Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver symbols : Galt save search
Global NASH Market to Soar to $2.71 Billion by 2023, Driven by Rising Prevalence of Silent Liver Disease
Published: 2023-11-11 (Crawled : 04:20) - prnewswire.com
IVA | $3.24 -1.52% -0.3% 13K
|
Health Technology
| Email alert
Add to watchlist
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
| Email alert
Add to watchlist
GNFT | $3.49 1.31% -6.4% 3.5K
|
Health Technology
| Email alert
Add to watchlist
ICPT | $19.0 -0.05% 4M
|
Health Technology
| Email alert
Add to watchlist
IVEVF | $3.73 0% 1K
|
n/a
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $71.2 0.49% 0.46% 300K
|
Health Technology
| Email alert
Add to watchlist
MDGL | $204.65 -6.29% -6.78% 350
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $135.35 -3.53% -4.19% 0
|
Health Technology
| Email alert
Add to watchlist
GLMD | $0.4 10.68% 6.18% 590
|
Health Technology
| Email alert
Add to watchlist
liver disease global nash market
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
Published: 2023-11-03 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: 1.98%
H: 0.49%
C: -2.43%
liver therapeutics
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
Published: 2023-10-03 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: -2.08%
H: 3.72%
C: 3.19%
cirrhosis liver positive meeting hypertension therapeutics study
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: 0.0%
H: 3.24%
C: -1.63%
cirrhosis liver update program therapeutics
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
Published: 2023-09-07 (Crawled : 17:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: 2.44%
H: 4.76%
C: 4.76%
cirrhosis liver therapeutics nash
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
Published: 2023-07-12 (Crawled : 21:00) - prnewswire.com
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: 1.7%
H: 0.01%
C: -0.32%
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
|
| O: -0.08%
H: 0.46%
C: -1.26%
MDGL | $204.65 -6.29% -6.78% 350
|
Health Technology
|
| O: 0.41%
H: 3.34%
C: 1.43%
LPCN | $4.44 -7.5% -6.43% 77
|
Health Technology
|
| O: 0.11%
H: 2.15%
C: 1.02%
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: 0.64%
H: 7.01%
C: 5.1%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: 0.69%
H: 1.02%
C: 0.29%
AKRO | $20.26 -3.52% -3.81% 20
|
Health Technology
|
| O: 0.78%
H: 1.1%
C: -0.15%
cirrhosis liver growth market
Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2023-03-16 (Crawled : 13:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: 1.58%
H: 1.03%
C: 0.0%
cirrhosis liver positive meeting therapeutics study
Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: 0.0%
H: 10.24%
C: 8.29%
cirrhosis liver therapeutics study
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
Published: 2023-01-24 (Crawled : 13:20) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: -0.89%
liver therapeutics
Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: -1.85%
H: 6.28%
C: 2.52%
cirrhosis liver meeting therapeutics positive study phase 2b
Liver Fibrosis Market to Surge at a CAGR of 15.9% by 2032 | DelveInsight
Published: 2022-09-05 (Crawled : 16:00) - prnewswire.com
SGMT | News | $4.17 -2.57% -3.13% 220K
|
Health Technology
| Email alert
Add to watchlist
ETNB | $8.58 -3.81% -3.84% 870K
|
Health Technology
| Email alert
Add to watchlist
MDGL | $204.65 -6.29% -6.78% 350
|
Health Technology
| Email alert
Add to watchlist
LPCN | $4.44 -7.5% -6.43% 77
|
Health Technology
| Email alert
Add to watchlist
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
| Email alert
Add to watchlist
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
| Email alert
Add to watchlist
fibrosis liver market
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022
Published: 2022-06-21 (Crawled : 12:20) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: -4.65%
H: 0.0%
C: 0.0%
cirrhosis liver therapeutics international
Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
Published: 2022-04-14 (Crawled : 15:00) - biospace.com/
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: 1.9%
H: 9.94%
C: 8.07%
cirrhosis liver therapeutics positive phase 2b
UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
Published: 2021-11-05 (Crawled : 22:00) - biospace.com/
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: 0.0%
H: 3.73%
C: -0.62%
liver
Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
Published: 2021-10-27 (Crawled : 12:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 0
|
Health Technology
|
| O: -0.31%
H: 0.92%
C: -1.85%
liver
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
MTH | $154.69 -2.21% 7.56% 64
|
Consumer Durables
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
IHT P | $1.3712 0.82% 6.48% 0
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.